Med-X, Inc. offering is now closed and is no longer accepting investments.

INVEST IN MED-X, INC. TODAY!

A LEADER IN GREEN SOLUTIONS

Your elevator pitch will go here

This Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

$859,941.60 Raised

REASONS TO INVEST

Reasons Icon

Your first reason to invest will go here

Reasons Icon

Your second reason to invest will go here

Reasons Icon

Your third reason to invest will go here

ABOUT

HEADQUARTERS

8236 Remmet Avenue
Canoga Park, CA 91304
VALUATION

Your elevator pitch will go here

TEAM

Dr. David Toomey
Dr. David Toomey
CEO and Director

Dr. David Toomey’s professional life has been spent as a family physician for more than 24 years and a Hospice Medical Director for the last decade. Over his many years as a physician, Dr. Toomey has also worked as a clinical investigator developing and testing, in clinical trials for multiple companies including major pharmaceutical companies.

Matthew A. Mills
Matthew A. Mills
COO and President

COO and President of Med-X, Inc. since inception, Matthew Mills is the company’s visionary, he utilizes and implements his vast experience and knowledge in product development, operations, business development, manufacturing, marketing and crowdfunding to position the company for short-term and long-term growth.

Ronald J. Tchorzewski
Ronald J. Tchorzewski
CFO, Director

CFO and Director Med-X, Inc. since inception, Ron Tchorzewski has over thirty-five years of experience in financial accounting for start-up and development companies, as well as reporting for publicly held companies from Silicon Valley and beyond. His chief financial officer level support, including business plan development, capital structure, and day-to-day accounting experience positions Med-X, Inc. for financial success.

Jennifer Mills

Jennifer Mills

Vice President, Corporate Secretary, Director

Jennifer Mills has been the Executive Vice President, Director and corporate secretary of Med-X, Inc. since its inception, Jennifer Mills has worked for multiple companies in her career as a high-level accounting liaison as well as in Human Resources and project management.

Nick Phillips

Nick Phillips

Vice President, Editor-in-Chief

Began his career in the Hollywood entertainment world and moved into digital marketing for multiple products in Los Angeles, which led him to The Marijuana Times. He drives The Marijuana Times digital magazine to fill a void in the reporting of the cannabis industry by providing a voice, education and news about the cannabis community. His skill set coupled with his dedication and attention to detail gives The Marijuana Times the leading edge in the industry.

Dr. Allan Kurtz

Dr. Allan Kurtz

Director

Dr. Allan Kurtz is board-certified in internal medicine and has owned and operated Allan Kurtz, a Professional Medical Corporation, since 1986. Dr. Kurtz has been the Medical Director of Warner Medical Center and the California Center of Longevity Medicine. He is also a long-time member of the American Osteopathic College of Internal Medicine.

Dr. Morton Hyson

Dr. Morton Hyson

Director

Dr. Morton Hyson is in private practice as a Board-certified Neurologist in Las Vegas, Nevada. He is also a Clinical Assistant Professor at Touro University in San Francisco, California, where he has been educating since September 2000. His professional affiliations include the American Medical Association, the American Academy of Neurology, the American Academy of Neurological and Orthopedic Surgeons, the American Headache Society.

Frederick Dashiell, Jr.

Frederick Dashiell, Jr.

Director

Mr. Dashiell has held various teaching positions at educational institutions such as Chapman University in Orange, California, University of California at Los Angeles and California Institute of Technology. Mr. Dashiell has also held various positions as a computer scientist as well as a research scientist in the private sector. Mr. Dashiell received a Bachelor of Science degree in physics from the University of North Carolina at Chapel Hill in 1963 and a Ph.D. in mathematics from the University of California at Berkeley in 1973.

TERMS

Med-X, Inc.
Overview
PRICE PER SHARE
$0.80
DEADLINE
Aug 13, 2020
VALUATION
AMOUNT RAISED
$859,941.60
Breakdown
MIN INVESTMENT
$420.00
MAX INVESTMENT
$9,200,000.00
MIN NUMBER OF SHARES OFFERED
525
OFFERING TYPE
Equity
ASSET TYPE
SHARES OFFERED
MAX NUMBER OF SHARES OFFERED
12,500,000

Maximum Number of Shares Offered subject to adjustment for bonus shares

Maximum [X] shares of common stock ($100,000)

Minimum [X] shares of common stock ($10,000)


Company
Enter Company Name
 

Corporate Address
Enter company street, city, state
 

Description of Business
Enter description of  business in a two quick sentences
 

Type of Security Offered
Enter securities offered (the "Shares", or the "Securities")
 
Purchase Price of Security Offered
Enter price of security
 

Minimum Investment Amount (per investor) 
Enter minimum investment amount












Perks

$[$$]Description of this tier of perk

$[$$]Description of this tier of perk

$[$$]+ Description of this tier of perk 

$[$$]Description of this tier of perk

PRESS

Article Image
Med-X, Inc. and Nature-Cide Sign Leading Pest Control Company Pestmaster Services to Direct Distribution Deal

"We have been focused on using safe practices since 1979," said Van Diepen. "Nature-Cide is exactly the kind of product line our customers demand that we use. We have tested these products for months and the results are there. We have a shared culture and mission to reduce risk in our communities. T

Article Image
Help your kids get through flu season with these thermal stuffed animals

These clever stuffed animals can be heated in the microwave or cooled in the freezer to make a hot compress or provide cold relief for inflammation. Each pack comes with two animals, and the options are adorable: rabbits, bears, elephants, koalas, monkeys, and hippos are all available to satisfy

Article Image
Going Green Again

Pennsylvanian Greg Pettis, a 23-year-veteran of the pest control industry, is an advocate of green pesticides. But that wasn’t always so.

Article Image
Nature-Cide, a Division of Pacific Shore Holdings, Inc. to Launch New Products and Labeling at National Hardware Show in Las Vegas, NV

Pacific Shore Holdings, Inc's. (OTCBB:PSHR), Nature-Cide Division, a pest management service company that's also engaged in the manufacturing of all-natural and eco-friendly pesticides, is excited to announce that they will be attending the National Hardware Convention in Las Vegas, NV, May 6 throug

Article Image
Nature-Cide Granular Insecticide

Nature-Cide Granular Insecticide is labeled for tick control, as well as for several other crawling pests and emerging larvae. The water-activated formula, which has 25(b)-exempt status, can be applied in the rain. It also can be added to fertilizer for a one-pass application on golf courses, turf,

ALL UPDATES

01.18.20

Two Year Independent Study in Florida Finds Nature-Cide as the Top Performing Pesticide in a Side-by-Side Study Against Top Selling Synthetic Products in Laboratory and Field Analysis for Mosquito Control

It has been a very busy month so far here in Los Angeles. We have a lot to cover and it is important that all shareholders receive this information. 

In this video update, Matthew brings us up to speed on developments to date in January 2020. 

Some of the topics Matthew touches on in the video are:

  • Status of the Custom Bed Bug Acquisition.

  • Announcement of Nature-Cide making the shortlist of approved pesticides for the cultivation of industrial hemp in the state of Kentucky. 

  • A statement that production begins on CBD Formulation of the Malibu Brands Pacific Pain Relief Cream. 

  • The introduction of Bugly, the first at-home retail membership for an all-natural “Do It Yourself” pest control program, that is a private label partnership with Nature-Cide.

  • Journal of the Florida Mosquito Control Association published a study showing the results of a two-year comprehensive study testing the efficacy of 25(b) products alongside the top three global pyrethroid products. The results are astonishing. 

  • Status of the pesticide toxicology testing overview. 

  • Review of product retail positions and status update on the 2020 inventory needs for all retail brands. 

  • Statement regarding Glendale Securities' position with the Company in preparation for the next steps after the potential acquisition. 

  • Status of moving the Reg. A+ offering away from StartEngine onto our own independent platform and the launch of a new Regulation Crowdfunding Offering that will be run and overseen by the StartEngine Broker-Dealer Division and run on their platform. 



Click the Play Button on the Video. If the video is not playing properly. Click Here.

Update: 

It has been a busy and productive start to the year for the Company. Again, we are thankful and very appreciative for all of your support and attention. Our Management expects to accelerate the Company with both product and service revenue goals while raising the capital needed to potentially position the Company to engage with the Investment Banking community and potentially list the Company on a national exchange. Everyone is working harder than ever to continue the expansion of the Company, as well as find liquidity for our shareholders in both the short and long term. We are hopeful that all of you are just as excited as all of the Med-X staff members and will continue to support our mission in the efforts of making a difference everyday and sharing our work with family and friends to help the cause move forward in a more rapid manner. 

Acquisition Strategy

The Custom Bed Bug acquisition is not finalized but it is close. Legal is tying up the loose ends on both sides. These things take time and we are grateful for all the hard work that has gone into this on both sides. Anything can happen with these things, and the deal won’t officially be done until we announce it. Once this is finalized we will be moving swiftly to start the talks with our other targets who are standing by waiting for engagement. This is the service piece of the business that the investment bankers that we are speaking with, are waiting for Med-X to finalize. 

Hemp Farming

We are excited to announce that the Kentucky Department of Agriculture has listed both the Nature-Cide All Purpose Concentrate and the Nature-Cide Outdoor as approved registered products for the cultivation of industrial hemp. This again solidifies our national position in the Cannabis and Hemp markets as a leading insecticide solution. Kentucky is a leading producer in US Industrial hemp and we see this as the important list to be on as other states follow Kentucky’s lead in regulating hemp farming in the US. We also believe that the Kentucky regulatory system will also be considered when, and if, the Federal Government opens the doors to THC cultivations with the seemingly imminent descheduling of Marijuana from the Controlled Substance Act. 

Click Here to Download the Kentucky Department of Agriculture Document

Malibu Brands

We are in multiple discussions with local contract manufacturing partners in regard to the mass production of the Malibu Brands products. This also includes the official launch of the Pacific Pain Relief Cream with added CBD. The Management team is in talks with several financial institutions who will potentially become critical partners for us as we begin to sell the Hemp-derived CBD products. The Company is also working diligently to get both the CBD Pain Relief Cream and the Non-CBD Pain Relief Cream registered with the FDA. This is a long process but if and when we are able to finalize this, we are confident our Healthcare Distribution partners will begin taking on that line of products as well placing the products into OTC pharmacies. 

Nature-Cide Breakout to Retail

We are also proud to announce our partnership with the team from Bugly, the first at-home retail membership for an all-natural “Do It Yourself” pest control program, that is a private label partnership with Nature-Cide. The Bugly project will be our first major step to provide the products directly to the consumer. We have to be strategic on how we enter the retail market as to not disrupt our positions in Professional Sectors. We believe this approach and this model have a great chance to be very successful. The model is seeing success in other DIY products like lawn care and we are excited to see how it performs as the insect season picks up. 

Nature-Cide Mosquito Efficacy

The Nature-Cide products have a great deal of efficacy to back up their claims and as a multi-state registered pesticide, we are forced to prove certain efficacy in order to get our labels registered. These products have been tested by professors and scientists on several occasions. But when we were recently informed about the latest findings from a two-year report published in the latest journal of the Florida Mosquito Control Association, we nearly fell out of our chairs. We knew the Nature-Cide products performed well on mosquitoes but we were thrilled to read that Nature-Cide was found to be the top-performing mosquito insecticide tested, regardless of its botanical status. Globally the fight to control mosquitos is the top public health priority with 17% of all infectious diseases transmitted globally are vector-borne. Mosquito vector control is the holy grail of pest control. Mosquito vector control is typically the responsibility of local, county, regional and federal municipalities. The scope and importance and potential implications of this study are not yet fully set in with the management team. The products hands down blew away our top green competitor “Essential IC3” and also outperformed, at all mixture rates, all of the top three biggest global sellers of synthetic pyrethroid mosquito insecticides. This was a third party scientific study done without our knowledge and it deserves everyone’s close attention. Please read the report. Below are the abstracts from both of the individual studies using both formulations. 

The trouble with Controlling Mosquitoes is the balancing act you have with the risk of spraying the chemicals. The chemicals can only be sprayed so much or else the risk of poisoning and polluting the environment become too high. With a 25(b) botanical products like Nature-Cide, you can apply the product freely with little to no risk of environmental and human contamination. This could be the break we have been waiting for. The last step is to finalize the findings with toxicology reports to confirm that the products do not pose a risk to water ecology and non-target pests like pollinators. 

Below we have included the Abstracts from the report and we highly suggest you download the full report and reviews, to see the results and the positive comments for yourself. 

Download the Full Report Here


EVALUATION OF PYRETHROID AND BOTANICAL BARRIER INSECTICIDES AGAINST AEDES ALBOPICTUS IN THE LABORATORY AND FIELD

STEVEN T. SMOLEROFF, CHRISTOPHER S. BIBBS, AND RUI-DE XUE

Anastasia Mosquito Control District, 120 EOC Drive, St. Augustine, FL 32092

Subject Editor: Seth Britch

ABSTRACT

Outdoor residual insecticide applications are useful for preventing or reducing mosquito populations at focal areas. Until recently, pyrethroids have been the only option for barrier sprays in mosquito control. In this study, three pyrethroid (Onslaught, Cyzmic CS, DeltaGard) and two botanical (Nature-Cide, Essentria IC3) outdoor residual insecticides were comparatively tested at low, mid, and high label rates against adult Aedes albopictus in both laboratory bioassays and field trials in St. Augustine, FL, from May-August 2017. Bioassays indicated NatureCide and Cyzmic CS were the most toxic across all three dilution ratios followed by DeltaGard, Onslaught, and Essentria IC3, respectively. In field trials Nature-Cide and Onslaught were the only products that reduced mosquito abundance at the low rate. However, at the mid rate Nature-Cide and Onslaught caused ~90% percent reduction of adult female Ae. albopictus in the field, the highest of all tested products. The performance of DeltaGard (79% reduction in field counts), Essentria IC3 (64%), and Cyzmic CS (36%) in the field were not similar to the laboratory results. The universally high performance of Nature-Cide indicates that mosquito control operations should expand consideration to botanical based insecticides for field operations.


SEMI-FIELD ULV EVALUATION OF AN ALL-PURPOSE BOTANICAL INSECTICIDE CONTAINING CEDARWOOD AND CINNAMON OILS AGAINST ADULT AEDES AEGYPTI

CHRISTOPHER S. BIBBS, KATHY SHIRLEY, DENA L. AUTRY, AND RUI-DE XUE

Anastasia Mosquito Control District, 120 EOC Drive, St. Augustine, FL 32092

Subject editor: Eva Buckner

ABSTRACT

Public health mosquito control operates with only two classes of mosquito adulticides: pyrethroids and organophosphates. Recent work improving the emulsification of essential oils has increased the potential for development of plant derived active ingredients. There is a growing body of literature on essential oils for various roles in mosquito management. Nature-Cide Pest Management (NCPM), a product available in private and commercial home pest control, uses a mixture of 25.3% cedarwood oil and 12.7% cinnamon oil as a Federal Insecticide, Fungicide, Rodenticide Act (FIFRA) exempt insecticide for both indoor and outdoor use. Recent investigations by the Anastasia Mosquito Control District of St. Johns County have found other FIFRA exempt products to be effective as a residual spray on vegetation. In continuing the exploration of botanical insecticides, NCPM was used in ultra-low volume (“ULV”) tests against Aedes aegypti (L.) within its 35-122 ml per L of water label rate. Applications at 35 ml/L resulted in 60-70% knockdown after 1 hr and mortality after 24 hr. Increasing the rate to 70 ml/L resulted in 100% knockdown and mortality across all replications. Crystalline precipitation of the microemulsion was observed in mix tanks after standing for at least 2 wk, but it was not apparent that the efficacy of the product was reduced as a consequence. Cedarwood oil and cinnamon oil are a beneficial combination for ULV adulticiding against mosquitoes and could have a beneficial role for integrated mosquito management.

Retail Inventory

Purchase Orders are already starting to roll in for Thermal-Aid and Nature-Cide. With word of the report about Nature-Cide starting to spread in social media, we need to make sure our inventory levels are adequate to fulfill these growing pains. Everything is seemingly ramping up across the board and we are going to need to keep up with the demand of positioning our high margin products over the next few months. 

Toxicology Reports

Several countries have been knocking on the door for months waiting for the Nature-Cide Toxicology reports. When the reports are completed, we will begin engagements and enter most of the other countries to continue the growth of the Nature-Cide brand world-wide. These reports are costly and require all of our focus to get this down, as we believe the rewards to be very beneficial for the Company. The need for the Nature-Cide products is much stronger overseas than in the US. Pesticide regulations are far more strict in all other countries vs. the US. The sooner we can complete the toxicology studies, the faster these products can go to Southeast Asia, Africa and South America where the governments of these countries spend hundreds of millions of dollars spraying toxic chemicals to maintain public health requirements on mosquito control and pest management. 

Listing

Glendale Securities has delivered the 15c2-11 information requirement package and we have several investment banks sitting on the sidelines waiting patiently for the Custom Bed Bug acquisition to be finalized. As soon as we hit our revenue milestones and have the capital on hand with a commitment from an Investment Bank, we plan to pull the trigger and list on an exchange when the timing is right and the market conditions are favorable. 

Crowdfunding Platforms

Very soon the Company will be pulling its Reg. A+ Offering off of the StartEgine platform and replacing it with a Regulation Crowdfunding Offering (“Reg CF”). We are doing this to fulfill our commitment to our broker-dealer NMS Capital and to allow ourselves the flexibility needed to go out and continue raising capital, with multiple Broker-Dealers by our side. This is the best move for the Company at this time. We are hopeful that the technology we have built for our new capital-raising platform will offer our investor relations and marketing team the transparency and flexibility needed to raise the capital rapidly that the Company needs. The Reg CF will still allow individuals who prefer the StartEngine Platform to continue to invest. However, moving forward in the coming days, all new Reg A+ investments will be processed via our new, independent platform on medxinvestor.com.  

As you can see, there are a lot of great things going on here at the Company, and we are confident in the direction we are headed. We need every staff member, associate and shareholders’ focus to share our mission of making a difference every day with friends and family so as to expand the work we are doing world-wide. 

I cannot thank each and every shareholder enough. We want to hear from you directly. If you have ideas or know people in states that can help our efforts, please call us. Together we can continue making a difference every day. 


Sincerely, 

Matthew Mills


DISCLAIMER AND FORWARD-LOOKING STATEMENTS 

The securities offered by Med-X, Inc. hereby are highly speculative. Investing in shares of MED-X, INC. involves significant risk. This investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment could be illiquid for an indefinite period of time. No public market currently exists for the securities and if and when a public market develops following this offering it may not continue. You should read the NEW Offering Circular as well as all Securities Exchange Commission filings before making any investment in the Company. 

This release may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the company incurring operating losses and experiencing unexpected material adverse events.

01.02.20

2019 Year-End Review and Outlook for 2020

Happy New Year! As we close out the end of this amazing year I wanted to take some time and reflect back on a few important milestones the company was able to accomplish in 2019 and then cover some important items as we start 2020. It was a very productive year and we are set up nicely to have an even more productive year in 2020.

A year in review:

  • Nature-Cide products were introduced and sold to the professional turf grass industry for the first time.
  • Nature-Cide’s international footprint grew with Rentokil in several new countries.
  • Nature-Cide committed to a larger strategic marketing plan with the largest pest control distributors and industry publications.    
  • The company launched its Acquisition Company Roll-Up Strategy and entered into talks with several targets in the pest control service arena. 
  • The company signed a letter of intent and is working to close its first pest control service acquisition.  
  • The company reserved the Nasdaq Symbol “MXRX”.
  • Malibu Brands Pacific Pain Relief Cream was launched. 
  • The company successfully closed its first Regulation A+ offering on StartEngine in June of 2019 capping the round off in the neighborhood of $7 million raised since 2016.
  • The company signed with broker-dealer NMS Capital to partner on its new Regulation A+ capital raise. 
  • The company launched the National Investor Network. 
  • The Marijuana Times helped break the story on contaminated cannabis oil being sold on the black market. 
  • Thermal-Aid products saw growth from Cardinal Health Distribution and direct-to-consumers.
  • Nature-Cide delivered hundreds of samples of products to professionals in 2019 as the word spread around the world.  
  • The company launched its own investment platform for its new Regulation A+ offering.
  • The company surpassed its 2018 revenue in Q4 and reached its 2019 revenue goals. 

It was a challenging but satisfying year for our company. All of the support from our shareholders and partners allowed us to keep this movement going in a positive direction. The brands themselves, especially Nature-Cide, has become globally known as a premier Green Pest Control product line.

2020 is going to require everyone at the company to work harder than they have ever worked. This is the year where we pick up where we left off with direct-to-consumer sales for Thermal-Aid and explore a consumer revenue stream with Nature-Cide for the first time. Our media divisions are positioned to continue to grow especially the National Investor Network. The Equity Crowdfunding Report is already quickly positioning itself as the only media outlet using video to specifically cover the Equity Crowdfunding Markets and new private equity investors are learning about its resources. International pesticide label registration processes for many major countries are underway and we hope for this long process to be completed in 2020 opening the international flood gates for Nature-Cide. Conversations continue with our largest OTC healthcare distributor, Cardinal Health, to increase the footprint of the Thermal-Aid products as well as the introduction of the Malibu Brands Pacific Pain Relief Cream into OTC pharmacies. The company roll-up strategy is scheduled to go into overdrive as our first acquisition wraps up in legal and hopefully it will be announced in early 2020. We have several targets waiting in the wings to see how this first acquisition goes and we are hopeful other like-minded companies are going to want to be a part of this movement. NMS Capital is dedicated to continuing to support our efforts to bring in institutional partners into the mix as we continue our commitment to a listing on a national exchange when the time is appropriate. 

Without the continued support from each and every one of our shareholders we could not have made the progress we did this year. We all look forward to continuing the GREEN movement in these industries that are truly being forced to accept the changes coming. Natural products and services will have a place at the table in 2020 and many years beyond. 

The management team is committed to continuing to keep all of our shareholders apprised and updated on a regular basis, and in 2020 the team will continue to make ourselves available to all of our shareholders anytime. 

I wrapped up the year with an interview with our Chief Media Officer, Nick Philips, on the Equity Crowdfunding Report. It is a long, comprehensive interview. If you are interested in hearing more about 2019 and 2020, we cover many topics in the interview. We are all excited about the show and the buzz it is generating in the equity crowdfunding world. You can watch it by signing up, or logging in if you are already a member of the National Investor Network


Happy New Year!

Sincerely, 

Matthew Mills

President & COO


VIDEO INTERVIEW

11.08.19

Med-X, Inc. Surpasses 2018 Revenue During the 4th Quarter of 2019 While in Final Stages of it’s First Pest Control Service Acquisition

In this update, Matthew reports on how 2019 revenues have already surpassed 2018 revenues across multiple divisions as well as how its potential acquisition could lead to engagements with large scale investors. This progress has motivated Med-X Management to prepare the company accordingly, as they meet with the potential sponsors to list the company. 



CLICK HERE TO WATCH VIDEO


Our largest Over The Counter or “OTC”  Pharmacy distributor Cardinal Health / RGH just placed an order to continue to distribute the Thermal-Aid product line throughout “OTC” pharmacies which are performing well and selling-through. We anticipate these orders to continue to increase in frequency and volume. 

This kind of traction coupled with our direct to consumer boost through Amazon, is forcing us to quickly ramp up our production for this line as PO’s from our distributors continue to get larger and inventory requirements from Amazon Fulfillment continue to increase and seemingly are snowballing. We need to be ready for 2020 because at these rates it is going to be a busy start to the year. 

We feel strongly that with all of this increased visibility and with these high sell-through rates it is only a matter of time before the bigger “OTC” retail players jump on board and begin to load the products as well, so we need to be ready!

Conversations have also continued to ramp up with many overseas pest control operation distributors. We are in talks with companies from Canada, Mexico, Indonesia, Nicaragua, Brazil, Peru, Australia, Saudi Arabia, Dubai, Bahrain, South Africa, United Kingdom, New Zealand, Malaysia, the Philippines, and South Korea. Governments in these countries continue to tighten regulations on the use of pesticides and these distributors are scrambling to get new products in place that will pass their toxicity and environmental impact requirements. 

The importation of pesticides into foreign countries requires the company to comply with each countries stringent regulatory red tape. We are working to have the Nature-Cide products fully scrutinized and registered in all of these countries. Once the studies are done we will be able to register our products on an individual basis with each country, all of which have their own requirements and processes that require the above-mentioned testing to be completed. This is an incredibly important time for our company to buckle down and invest as much of our resources as possible in getting the Nature-Cide products positioned accordingly. Once this is accomplished, Nature-Cide products and protocols could very well end up leading the all-natural global pest control markets.  

The company is also in the final stages of an acquisition of a pest control service company that is doing over $1M annually in service revenue. 

With this acquisition, our plan is to significantly increase revenue in 2020 compared to 2019 starting in Q1. We are all hopeful and waiting patiently for the legal teams to finalize agreements, so the company can make the acquisition official.  We are also hopeful that several other acquisition targets will fall into line once the first transaction is complete, and word continues to spread that we are actively acquiring like-minded pest control companies. 

The revenue growth and acquisition plans have various large scale investment funds watching the company very closely, and we are excited to have the opportunity to present our work accordingly. This said we are meeting with an interested sponsor in the coming days to discuss the process of a 15c2-11 filing which is the first step in the potential listing of the company. The goal is to organize and engage with the perfect financial partner to support our growth and acquisition plans, then expand further if and when we list in a public marketplace.   

The team is dedicated to working harder than ever in the final weeks of 2019, in order to make sure the company continues to grow and we begin 2020 in the best shape we have ever been in. We are all excited to see what the future holds.

Matthew is available to discuss the growth of the company one-on-one, so don't hesitate to reach out and schedule an appointment. 


Thank you for all of your continued support. 


Nick Phillips

Med-X Team


DISCLAIMER AND FORWARD-LOOKING STATEMENTS 

The securities offered by Med-X, Inc. hereby are highly speculative. Investing in shares of MED-X, INC. involves significant risk. This investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment could be illiquid for an indefinite period of time. No public market currently exists for the securities and if and when a public market develops following this offering it may not continue. You should read the NEW Offering Circular as well as all Securities Exchange Commission filings before making any investment in the Company. 

This release may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the company incurring operating losses and experiencing unexpected material adverse events.


10.18.19

Nature-Cide Shines at PestWorld 2019

In this update, COO, Matthew Mills reports from the TradeShow floor at PestWorld 2019.


CLICK HERE TO WATCH VIDEO


At the show, the team has been meeting with hundreds of business owners who are all interested in learning more about adding green options to their product offerings. Owners of pest control companies from all over the world have all met in one place to get educated and to network. “We have been doing this show for a few years now and this year is by far the most attention we have had around the company,” says Matthew Mills. “When we first started doing this a few years ago people would come up to us and not recognize the need for green pest control products, as well as believing that Nature-Cide couldn’t possibly be a viable solution. Now the word has spread and people from all over the country and the world are waiting in line to talk to us. The market is changing really fast. Those same people are coming back to learn more because their customers are asking for green options. We are in a really great place,” says Matthew. 

The show is known worldwide as the premier pest control tradeshow and with that comes numerous face to face meetings with international companies that we typically don’t get much face time with. Today, Matthew met with several large scale pest control company owners who want the Nature-Cide products in their countries. He met with leadership from companies in several strong and emerging markets but more significant and important were the meetings with companies in Malaysia, Brazil, and Korea as we have been in communication with them for weeks. It is always very nice to put faces to names. We walked away with some very positive takeaways and solid commitments to work together with multiple international regulatory bodies to get the Nature-Cide products registered for usage within the various countries.

We had multiple investment banking groups who have had their eyes on us and decided to come down and see the attention we were generating first hand. These groups are going to continue to dig in as it appears that they like the company’s positioning, especially on the Nature-Cide front. The continued hope is we find more institutional partners who are trying to diversify by investing in environmentally friendly companies.  

Matthew had several important meetings with the leadership teams from our Distribution partners at Target-Specialty Products and Univar. It is critical that these relationships continue not only to be beneficial to all parties but to also flourish in 2020. The distributors have again given us their word that they will continue to push our products as one of the top-performing effective natural product lines. These multi-billion-dollar businesses see the green wave coming and they want to be a part of it.   

We also locked down some commitments on the retail side of things. We cannot fully disclose all the details yet, but we are hopeful that this relationship will be very fruitful. So stay tuned for that announcement in the coming weeks. 

This truly is a very exciting time for Med-X, Inc. We have a solid position in several markets with proprietary products and solutions that have a great upside in markets that need new life. 

Without each and every investor’s focus, we could not continue to grow. We appreciate all of your support. 

If you want to speak directly with Matthew and hear more about the events that took place at the show, please reach out to our investor relations department so we can put something on the books. If you do not have a point of contact yet, please let us know and someone will follow up accordingly. 


Nick Phillips

Med-X Team


DISCLAIMER AND FORWARD-LOOKING STATEMENTS 

The securities offered by Med-X, Inc. hereby are highly speculative. Investing in shares of MED-X, INC. involves significant risk. This investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment could be illiquid for an indefinite period of time. No public market currently exists for the securities and if and when a public market develops following this offering it may not continue. You should read the NEW Offering Circular as well as all Securities Exchange Commission filings before making any investment in the Company. 


This release may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the company incurring operating losses and experiencing unexpected material adverse events.

10.10.19

Nature-Cide Cannabis Cultivation Customers Should All Test Negative for the Harmful Chemicals Potentially Causing the Recent National Public Health Crisis

In this Update, COO, Matthew Mills, talks about how the Nature-Cide team and The Marijuana Times team have been warning and covering the potential for a serious national crisis involving Cannabis laced with dangerous pesticides for over the past three years.

CLICK HERE FOR VIDEO


Although the current situation is sad and scary, it does not come as a surprise to anyone here at Med-X, Inc. If you are unaware of the developments, it has been confirmed by the CDC that illegal cannabis vape cartridges are the leading culprit for the 12 deaths and over 800 hospitalized. Investigations are on-going and are proving that nearly all black market cannabis extracts contain dangerous levels of Myclobutanil, a synthetic chemical when burned turns into Hydrogen Cyanide. This is one of many chemicals legal and illegal growers use to remediate pests in commercial cannabis grows. Matthew warns that the media is only reporting part of the problem, as smoking cannabis that has been treated with the same toxic chemicals, can still emit poisonous gases when smoking cannabis flower. 

All Nature-Cide customers who use Nature-Cide in their facilities to grow organic cannabis should all test negative and all products should be deemed safe for consumption by regulators. The Marijuana Times has been covering this since 2016 and also broke a story in June of this year which reported on a massive illegal outlaw operation in Mendocino County where the Sheriff randomly tested the confiscated products and the results were astounding. 

https://www.marijuanatimes.org/pesticides-in-illegal-pot-a-budding-health-crisis/

Two months later, people started getting sick and dying. Our advice to everyone is please, don’t consume Cannabis unless you buy it from a legal dispensary or you grow it yourself. 

Matthew also invites any interested investors to join him and the Nature-Cide team as they travel to San Diego, California next week for PestWorld 2019. Matthew has some big meetings with large operators in the US, South Korea, Malaysia, Australia, the Middle East and more. This is a great opportunity to talk to our customers and distributors as well as really see for yourself how fast this brand is growing domestically and internationally. 

We are prepped and ready for the best trade show the company has ever had. This is a very exciting time and Matthew looks forward to sharing it with anyone who wants to attend. 

We appreciate all of you for your continued support as we enter the fourth quarter and are working towards some strong initiatives, that we hope will prove to be our best year ever. 


Nick Phillips

Med-X, Inc.


DISCLAIMER AND FORWARD-LOOKING STATEMENTS 

The securities offered by Med-X, Inc. hereby are highly speculative. Investing in shares of MED-X, INC. involves significant risk. This investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment could be illiquid for an indefinite period of time. No public market currently exists for the securities and if and when a public market develops following this offering it may not continue. You should read the NEW Offering Circular as well as all Securities Exchange Commission filings before making any investment in the Company. 


This release may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the company incurring operating losses and experiencing unexpected material adverse events.


09.30.19

Thermal-Aid Brand Gears Up for Another Busy Fourth Quarter

In this update, COO, Matthew Mills, takes us out of the boardroom and into the Med-X, Inc. facility once again to review our Thermal-Aid brand, and cover new developments as we enter the brand's historically best time of year, the fourth quarter. 


CLICK HERE TO WATCH VIDEO


Currently, Thermal-Aid products hold nationwide retail positions in retailers like;

Ralphs Supermarket Pharmacy

King Soopers Supermarket Pharmacy 

City Market Supermarket Pharmacy 

Kroger (East Coast) Supermarket Pharmacy 

Approximately 1,500 Independent Pharmacies in various regions around the country.


These accounts are all serviced by Cardinal Health and RGH Distribution. These positions take years to obtain and we feel fortunate to continue our customer growth, due to year over year sell-through. 

On the direct to the consumer side, all of the Thermal-Aid products are sold directly to the consumer via our own ecommerce platform - thermalaidproducts.com.

You can also buy the products directly from the largest Flexible Spending Account retailer, FSAstore.com. All these products are approved for FSA sales as well as insurance approved so Doctors can cover the cost of the product through medical insurance reimbursement when they provide these to their patients when in their offices. 

The newest development for the Thermal-Aid brand is a new Partnership with a reputable marketing agency with a proven track record for optimizing Amazon seller strategies. As of this week, we have re-worked all of our brand product listings and have gone through the rigorous process of preparing all of our Thermal-Aid products to be Fulfilled by Amazon (“FBA”). This will give our products Prime Status, the Amazon badge and the ability to ship these products the same day and even with Prime Now within hours depending on the location of the customer. In conjunction with our planned Amazon marketing initiatives, we feel strongly that this is what is going to put us on another level from a direct to consumer retail position. The first wave of FBA inventory is being processed now by Amazon and we should know more in the coming weeks.

These initiatives have been in the making for months now, and we hope to close out 2019 with a solid push, work out the kinks and hit the ground running at full steam going into 2020. 

If you or a family member suffers from Migraine Headaches, arthritis pain or any other condition or you have kids and want to get a sample of the products to let us know by sending us an email and someone will follow up accordingly to make that happen. 


Sample Product Inquiries: info@medx-rx.com 


Thanks for your continued support. 


DISCLAIMER AND FORWARD-LOOKING STATEMENTS 

The securities offered by Med-X, Inc. hereby are highly speculative. Investing in shares of MED-X, INC. involves significant risk. This investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment could be illiquid for an indefinite period of time. No public market currently exists for the securities and if and when a public market develops following this offering it may not continue. You should read the NEW Offering Circular as well as all Securities Exchange Commission filings before making any investment in the Company. 


This release may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the company incurring operating losses and experiencing unexpected material adverse events.

09.25.19

Strict International Regulations on Pesticides Continue to Fuel Nature-Cide Expansion and Growth Outlook

In this update, COO, Matthew Mills takes you inside the Med-X facility for a look at the day's preparations for several existing customers and a few new international Natura-Cide orders. The international interest in Nature-Cide is a clear indicator of the growing trend of the professional pesticide industry moving to include safer green options. 


CLICK HERE TO VIEW VIDEO


The team is making final preparations for what we hope to be our most important and successful appearance at the largest pest control trade show in the world, PestWorld 2019. This year’s trade show is taking place in San Diego from October 15th to October 18th. If you want to meet with Matthew Mills and see the action for yourself let us know so we can make arrangements in advance for your visit. Our distributors are all excited to showcase the Nature-Cide brand and we would love the opportunity for any shareholder to actually see the excitement around Nature-Cide in the broad scope of the international community. 


Matthew and the management team is also focused on providing updates more frequently as we move forward. Our commitment to providing reliable communications to our shareholders is critical. Expect a few more very important updates coming down the pipeline in the next couple of weeks leading up to Pestworld and post trade show.


Thanks for your continued support, 


Nick Phillips

Med-X, Inc.


DISCLAIMER AND FORWARD-LOOKING STATEMENTS 

The securities offered by Med-X, Inc. hereby are highly speculative. Investing in shares of MED-X, INC. involves significant risk. This investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment could be illiquid for an indefinite period of time. No public market currently exists for the securities and if and when a public market develops following this offering it may not continue. You should read the NEW Offering Circular as well as all Securities Exchange Commission filings before making any investment in the Company. 


This release may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the company incurring operating losses and experiencing unexpected material adverse events.

08.21.19

Med-X, Inc. Qualified by the SEC to Launch Second Crowdfunding Offering in Conjunction with Investment Banking Firm NMS Capital Advisors, LLC

In this video update, COO, Matthew Mills, discusses the companies going forward strategy for raising capital with our investment banking partner, NMS Capital Advisors. He reveals a new version of the Malibu Brands Pacific Pain Relief Cream and also discusses the companies strategy to increase revenue via acquisitions to position the company to list on a national exchange like the Nasdaq. 

The press release can also be seen in its entirety below.


Click Here to Watch Video



Link to Press Release

LOS ANGELES, Aug. 15, 2019 /PRNewswire/ -- Med-X, Inc. -- On August 12, 2019, the Securities Exchange Commission (SEC) qualified Med-X, Inc. (Med-X) to begin the company's second Regulation A+ Equity Crowdfunding Offering. This time Med-X will be working with a Broker/Dealer, NMS Capital Advisors, LLC ("NMS Capital"), in selling the offering which is now live on the crowdfunding portal StartEngine.com. The company plans to also link and use its own web site resources which include, Med-X, Inc. the official company website, as well as placing links and information regarding the company's offering on its divisional and subsidiary web properties, such as Thermal-Aid, Nature-Cide, The National Investor Network, Malibu Brands and The Marijuana Times.

"Regulation A+ allows us to advertise and reach out to all investors, not just wealthy accredited investors who comprise the top few percents of the country. While we do have a large number of the wealthy accredited investors, it is our philosophy to let all of our customers who use our products and or services, our small business partners, friends, family and fans to all participate in our company mission," explained Med-X President and COO, Matthew Mills.

For this offering, while allowing the "Working Class American" to buy Med-X shares for as little as $420 for 525 shares, Med-X management and NMS Capital are working together to create a syndicated network of Broker/Dealers to accelerate the offering. This will provide Med-X with the ability to execute on immediate key growth strategies. 

For example, Med-X is in the midst of discussions and negotiations with multiple like-minded Eco-friendly pest control service companies, for strategic acquisition and or partnerships within the Nature-Cide's Service Division. This strategy is expected to fast-track the use of Nature-Cide's environmentally friendly and effective products within residential and wide-spread commercial applications nationwide. Other growth opportunities for Med-X divisions include adding new products to Nature-Cide's product line up, while expanding Malibu Brands new Pacific Pain Relief Cream to include a legal hemp CBD infused formulation version of the product, along with Thermal Aid's product lines and the Media Divisions, which includes the Marijuana Times and the new National Investor Network.

ABOUT MED-X, INC. 

Med-X, Inc. is a Nevada corporation formed in February 2014 to support the fast-paced environmentally friendly green scene products and services sectors, with its Nature-Cide, Malibu Brands and Thermal-Aid divisions as well as the emerging hemp and cannabis industry through such activities as compound identification and extraction of the identified cannabidiol (CBD) compounds for the present medical industry demand. The company's digital magazine, The Marijuana Times, publishes high quality media content for the medical cannabis community to potentially generate revenue from advertisers as well as sell industry related merchandise to consumers. For more information regarding Med-X, Inc., please visit www.medx-rx.com, email info@medx-rx.com or call 818-349-2870.

DISCLAIMER AND FORWARD-LOOKING STATEMENTS 

The securities offered by Med-X, Inc. hereby are highly speculative. Investing in shares of MED-X, INC. involves significant risk. This investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment could be illiquid for an indefinite period of time. No public market currently exists for the securities and if and when a public market develops following this offering it may not continue. You should read the NEW Offering Circular as well as all Securities Exchange Commission filings before making any investment in the Company. 

This release may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the company incurring operating losses and experiencing unexpected material adverse events.

JOIN THE DISCUSSION













0/2500

HOW INVESTING WORKS

Cancel anytime before 48 hours before a rolling close or the offering end date.

WHY STARTENGINE?

REWARDS

We want you to succeed and get the most out of your money by offering rewards and memberships!

SECURE

Your info is your info. We take pride in keeping it that way!

DIVERSE INVESTMENTS

Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.

RAISED
$859,941.60
INVESTORS
401
MIN INVEST
$420.00
VALUATION

@ 2022 All Rights Reserved

Apple Store Logo

Get To Know Us

Our Team

Careers

Blog

Important Message

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTMENTS ON STARTENGINE ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.


www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.


Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.


Investment opportunities posted and accessible through the site are of three types:


1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.


Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.


By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.


Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.


California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.


StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.